Scotland’s First Tear Biomarker Analyser for Dry Eye: Introducing the Seinda i‑ImmunDx™ at Peter Ivins Eye Care
Dry eye is one of the most common reasons people visit an optometric practice, yet it’s also one of the most misunderstood. Many patients arrive believing it’s simply “not enough tears”, or that a different bottle of drops will finally fix it. In reality, dry eye disease is a complex, multifactorial condition involving tear film instability, inflammation, surface damage and, in some cases, altered nerve signalling. That complexity is exactly why the gold standard approach to dry eye isn’t guesswork—it’s measurement, precision diagnosis, and structured follow‑up.
At Peter Ivins Eye Care, our Dry Eye Clinic was built on that philosophy from day one. We launched our clinic back in 2010 and have since treated hundreds of patients with tailored, evidence‑led care. Over the years we’ve worked hard to bring the most advanced diagnostic and therapeutic options to Scotland—often first. That’s not a slogan; it’s been our commitment.
And today, we’re proud to announce another Scotland first:
We are the first practice in Scotland to introduce the Seinda i‑ImmunDx™ Analyzer to our Dry Eye Clinic—allowing us to measure key tear biomarkers at the point of care.
This is a major step forward for diagnosis, treatment selection, and ongoing tracking—particularly for patients whose symptoms don’t neatly match their clinical signs, those with persistent inflammation, or those who have tried “everything” and still aren’t comfortable.
Why Biomarkers Matter in Dry Eye (and why the future is objective)
Dry eye disease is defined in modern consensus as a loss of tear film homeostasis—and the research community has repeatedly emphasised the roles of inflammation, hyperosmolarity, and surface damage. What that means in practice is simple: two people can both say “my eyes feel gritty,” yet the underlying drivers can be very different.
- One patient may have primarily evaporative dry eye, often linked to Meibomian Gland Dysfunction (MGD).
- Another may have aqueous deficiency, where the lacrimal system isn’t producing enough of the watery component.
- A third may have prominent inflammatory activation, where the ocular surface is stuck in a cycle of immune‑driven damage.
- And some patients have overlapping mechanisms—or an additional layer such as allergy or neuropathic pain.
The challenge is that dry eye symptoms alone do not reliably tell us which mechanism is dominant. Even traditional clinical tests can sometimes be variable day‑to‑day. That’s why the dry eye field has increasingly focused on biomarkers: measurable molecules in tears that provide objective insight into what’s happening on the ocular surface.
Dry Eye Biomarkers help us answer key questions:
- Is this patient’s dry eye inflammatory right now—or not?
- Are we treating the right thing, or just smoothing the surface temporarily?
- Is the treatment working biologically, not just symptomatically?
- Can we confidently step down therapy—or do we need to escalate?
This is where the Seinda i‑ImmunDx™ becomes a genuine clinical game‑changer.
What Is the Seinda i‑ImmunDx™ Analyzer?
The i‑ImmunDx™ platform is a tear‑based point‑of‑care testing system that uses a very small tear sample (micro‑volume) to quantify specific biomarkers. The system combines:
- A micro‑capillary tear collection method designed for minimal sample volume
- A set of test cassettes for specific biomarkers
- The i‑ImmunDx™ Analyzer, which reads the cassette and provides results rapidly
What we like about the i‑ImmunDx™ approach is that it brings laboratory‑style biomarker insight into a real clinical workflow—without sending samples away, waiting days, or guessing based on incomplete information.
Which biomarkers can it measure?
The i‑ImmunDx™ ecosystem is designed to support multiple tear biomarkers relevant to ocular surface disease—most notably:
- MMP‑9 (a marker associated with ocular surface inflammation and epithelial barrier disruption)
- IgE (often associated with allergic disease)
- Lymphotoxin‑alpha (LTα3 / LTA) (investigated in relation to immune regulation and dry eye phenotyping)
- Additional cytokines such as IL‑6 and IL‑8 are being developed within the same platform ecosystem.
In a busy dry eye clinic, this is valuable because dry eye doesn’t exist in isolation. Allergic conjunctivitis can mimic dry eye. Inflammation can dominate even when meibomian glands look only mildly obstructed. Some patients have both.
Why This Matters for Patients: Diagnosis, Targeted Management, and Tracking
1) Better Diagnosis: Moving beyond “it looks dry”
A modern dry eye assessment should do more than confirm dryness. It should determine:
- the subtype (evaporative, aqueous deficient, mixed)
- the drivers (MGD, inflammation, allergy, lid disease, systemic factors, iatrogenic contributors)
- the severity and risk of progression
- and what we should treat first
Biomarker testing adds another dimension: it helps identify whether active inflammation is part of the current picture. That matters because inflammatory dry eye typically responds better when we treat the inflammatory component directly—rather than relying solely on lubricants and warm compresses.
2) More Personalised Treatment Selection
Dry eye therapies are not one‑size‑fits‑all. In our clinic, we often combine:
- home care fundamentals (lid hygiene, compresses, environmental changes)
- in‑practice therapies (such as IPL, LLLT, BlephEx, Zest, Meibmian gland expression, meibomian gland probing etc)
- tear substitutes and protective strategies
- targeted anti‑inflammatory approaches when indicated
When we can objectively measure inflammatory markers, it helps us make more confident decisions about:
- whether anti‑inflammatory strategies are appropriate
- the expected treatment timeline
- when to escalate or combine in‑practice procedures with medical management
- how to tailor maintenance so results last
3) Objective Tracking: “Are we winning?”
One of the most frustrating aspects of dry eye for patients is the stop‑start cycle:
- you try something, feel better
- then symptoms return
- you’re unsure what actually worked—or why it changed
Tear biomarkers give us a way to track progress objectively. If symptoms improve but inflammation remains high, we may need to keep going. If inflammation resolves and your tear film stabilises, we can maintain with lighter‑touch strategies. This kind of tracking is how we make dry eye care predictable, structured, and patient‑specific.
How This Fits with Our Long History of “Firsts” in Scotland
Bringing in the i‑ImmunDx™ is not an isolated decision—it’s a natural continuation of our dry eye journey. We’ve always invested in the tools and training that allow us to do more than standard practice, because dry eye patients deserve more than generic advice.
Our Scotland‑leading milestones include:
- Dry Eye Clinic established in 2010 – helping hundreds of patients
- First practice in Scotland to use IPL in dry eye
- First practice in Scotland to introduce the Oculus Keratograph 5 (K5) dry eye suite
- First practice in Scotland to fit an amniotic membrane for dry eye
- First practice to fit scleral lenses for dry eye
- First practice in Scotland to use BlephEx for blepharitis treatment
- First practice in Scotland to use InflammaDry MMP‑9 testing
- Now: First in Scotland to introduce dry eye biomarker in the Seinda i‑ImmunDx™ Analyzer for tear biomarker assessment
This is what we mean when we say we’re a dry eye clinic. We don’t simply treat symptoms. We build a complete clinical pathway that evolves with the evidence.
Our Approach: Expertise You Can Trust
A dry eye clinic is only as good as the team interpreting the data.
Craig McArthur, practice owner and a recognised dry eye expert, has lectured extensively on ocular surface disease and contributes regularly to leading professional publications including Optician and Optometry Today. As a clinic, we continuously train and update our protocols in line with the latest international consensus and research.
Dry eye is nuanced. It demands time, careful testing, and meaningful follow‑up. That’s why our clinic model prioritises:
- comprehensive assessment
- clear explanations (without jargon)
- a staged management plan
- measurable outcomes
- and ongoing support rather than “one‑off” appointments
What to Expect If You Attend Our Dry Eye Clinic (Now with Dry Eye Biomarker Testing)
Every patient journey starts with understanding your specific condition, not applying a generic solution.
Step 1: Comprehensive Dry Eye Assessment
We assess the tear film and ocular surface using modern diagnostic methodology to identify:
- tear stability
- ocular surface staining patterns
- lid margin health
- meibomian gland function and structure
- blink quality and contributing lifestyle factors
- and relevant medical history / medications
Step 2: Tear Biomarker Testing (when appropriate)
The i‑ImmunDx™ testing may be particularly helpful when:
- signs and symptoms don’t align
- inflammation is suspected
- previous treatment hasn’t delivered stable relief
- allergy and dry eye need differentiating
- we need objective tracking over time
Testing is quick and uses only a tiny tear sample. Results are available during your appointment, allowing us to discuss what they mean and how they influence your plan.
Step 3: Personalised Management Plan
We build your plan around:
- your dry eye subtype and drivers
- your symptom pattern and triggers
- your lifestyle (screen use, environment, contact lenses, make‑up practices)
- and your clinical findings, including biomarkers where used
Step 4: Follow‑up and Tracking
Dry eye is typically chronic. The goal isn’t just a good week—it’s stable comfort long term. Follow‑ups allow us to:
- assess response
- refine the plan
- support adherence
- and track improvement with both traditional clinical measures and biomarkers when appropriate
Why This Is Good News for Dry Eye Patients in Scotland
Dry eye care is changing. The direction of travel in global research is clear: toward precision diagnosis and personalised management. Tear biomarker testing brings us closer to that goal—helping us identify inflammatory activity, guide treatment choices, and monitor progress in a way that is more objective than symptoms alone.
Introducing the Seinda i‑ImmunDx™ Analyzer is another major step in ensuring our patients benefit from the best that modern dry eye science can offer—here in Bearsden, without needing to travel far.
If you’ve been struggling with dry eye—whether for months or years—our message is simple:
You don’t have to keep guessing. We can measure what’s happening and build a plan around you.
Book an Appointment
To learn more or to book a Dry Eye Clinic assessment, visit: dryeyescotland.co.uk
Or contact our team at Peter Ivins Eye Care, Bearsden.
✅ SEO‑Optimised FAQs for the i‑ImmunDx™ Dry Eye Blog
FAQs
What is tear biomarker testing for dry eye?
Tear biomarker testing is a diagnostic method that measures specific molecules in the tear film to help identify inflammation, allergy, or immune activity contributing to dry eye disease. It provides objective information beyond symptoms alone.
What is the Seinda i‑ImmunDx™ Analyzer?
The Seinda i‑ImmunDx™ Analyzer is a point‑of‑care diagnostic system that measures biomarkers in tears using a very small sample, allowing us to assess dry eye‑related inflammation and other ocular surface conditions during your appointment.
Why are dry eye biomarkers important in dry eye disease?
Dry eye symptoms do not always match what we see on examination. Biomarkers help us identify hidden inflammation or allergy‑related activity, enabling more precise diagnosis, targeted treatment, and better long‑term outcomes.
What does MMP‑9 mean in dry eye disease?
MMP‑9 is an enzyme associated with ocular surface inflammation and epithelial damage. Elevated levels suggest active inflammatory dry eye and can help guide decisions about anti‑inflammatory treatment.
How is tear biomarker testing different from a standard dry eye test?
Standard dry eye tests assess tear stability, quantity, and surface damage. Tear biomarker testing adds a molecular layer, showing whether inflammation or immune activity is present, helping us personalise treatment more accurately.
Is tear biomarker testing painful or invasive?
No. Tear biomarker testing is quick, gentle, and non‑invasive. It requires only a tiny tear sample and does not involve needles or eye drops that sting.
Who should consider tear biomarker testing for dry eye?
Tear biomarker testing may be helpful if you have persistent dry eye symptoms, limited response to previous treatments, suspected inflammatory dry eye, overlapping allergy symptoms, or fluctuating signs and symptoms.
Can tear biomarkers help differentiate dry eye from allergy?
Yes. Certain biomarkers, such as IgE, are associated with allergic eye disease. Testing can help us distinguish between allergy‑driven symptoms and inflammatory dry eye, which often require different treatments.
Can tear biomarker testing help if my dry eye treatments haven’t worked?
Yes. Biomarker testing can reveal whether ongoing inflammation or immune imbalance is limiting treatment success, allowing us to adjust or refine your management plan.
How long does i‑ImmunDx™ testing take?
The test itself takes only a few minutes, with results available during your appointment so we can discuss them immediately and incorporate them into your treatment plan.
Will I still need a full dry eye assessment if I have biomarker testing?
Yes. Biomarker testing complements, but does not replace, a comprehensive dry eye assessment. We use it alongside clinical examination, imaging, and symptom analysis for a complete picture.
Why is Peter Ivins Eye Care introducing tear biomarker testing?
We introduced tear biomarker testing to improve diagnostic accuracy, personalise treatment, and objectively track progress—continuing our long history of leading dry eye innovation in Scotland.
Is Peter Ivins Eye Care the first clinic in Scotland to offer this technology?
Yes. We are the first practice in Scotland to introduce the Seinda i‑ImmunDx™ Analyzer as part of a dedicated Dry Eye Clinic.
How does biomarker testing fit into your dry eye treatment approach?
We use biomarker testing to support evidence‑based decision‑making, helping us choose the right treatments, monitor response, and adjust care over time rather than relying on trial and error.
Can tear biomarkers be used to track dry eye improvement over time?
Yes. Repeat testing can show whether inflammation is reducing, helping us objectively assess whether treatment is working and when maintenance strategies are appropriate.
How often should tear biomarker testing be repeated?
This depends on your condition and treatment plan. In some cases, testing is done at baseline and after treatment to monitor response; in others, it may only be used once to guide diagnosis.
Is tear biomarker testing available in Glasgow or Bearsden?
Yes. Tear biomarker testing using the i‑ImmunDx™ Analyzer is available at our Bearsden practice as part of the Peter Ivins Eye Care Dry Eye Clinic.
How do I book a dry eye assessment with biomarker testing?
You can book a Dry Eye Clinic appointment via our website, dryeyescotland.co.uk, or by contacting our practice directly. We’ll advise whether biomarker testing is appropriate for you.
What is inflammatory dry eye?
Inflammatory dry eye is a form of dry eye disease where immune‑driven inflammation damages the ocular surface and tear film, often requiring targeted anti‑inflammatory treatment.
Why don’t dry eye symptoms always match test results?
Dry eye affects both the tear film and ocular nerves, meaning symptoms and clinical signs don’t always correlate. Biomarkers help reveal underlying activity that may not be visible on examination alone.
Is dry eye a long‑term condition?
For many people, dry eye is chronic but manageable. With accurate diagnosis, targeted treatment, and proper follow‑up, long‑term comfort is achievable.